Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 1.39
6.11 %
$ 6.68 M
Market Cap
-0.6
P/E
1. INTRINSIC VALUE
Balance Sheet
Intelligent Bio Solutions Inc.
| Current Assets | 8.53 M |
| Cash & Short-Term Investments | 6.3 M |
| Receivables | 978 K |
| Other Current Assets | 1.25 M |
| Non-Current Assets | 5.24 M |
| Long-Term Investments | 0 |
| PP&E | 873 K |
| Other Non-Current Assets | 4.37 M |
| Current Liabilities | 5.45 M |
| Accounts Payable | 602 K |
| Short-Term Debt | 1.06 M |
| Other Current Liabilities | 3.78 M |
| Non-Current Liabilities | 145 K |
| Long-Term Debt | 81.3 K |
| Other Non-Current Liabilities | 63.6 K |
EFFICIENCY
Earnings Waterfall
Intelligent Bio Solutions Inc.
| Revenue | 3.11 M |
| Cost Of Revenue | 1.69 M |
| Gross Profit | 1.43 M |
| Operating Expenses | 11.7 M |
| Operating Income | -10.3 M |
| Other Expenses | -92.2 K |
| Net Income | -10.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Intelligent Bio Solutions Inc.
| Net Income | -10.2 M |
| Depreciation & Amortization | 1.21 M |
| Capital Expenditures | -221 K |
| Stock-Based Compensation | 230 K |
| Change in Working Capital | -702 K |
| Others | -258 K |
| Free Cash Flow | -9.79 M |
Wall Street Analysts Price Targets
Intelligent Bio Solutions Inc.
INBS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
INBS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Intelligent Bio Solutions Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Oct 04, 2023
|
Bought
5 K USD
|
TOWERS CHRISTOPHER
Director
|
+ 9090
|
0.55 USD |
|
1 year ago
Oct 04, 2023
|
Bought
0 USD
|
TOWERS CHRISTOPHER
Director
|
+ 9090
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought
0 USD
|
TOWERS CHRISTOPHER
Director
|
+ 9090
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought
62 K USD
|
Sakiris Spiro Kevin
Chief Financial Officer
|
+ 112727
|
0.55 USD |
|
1 year ago
Oct 04, 2023
|
Bought
0 USD
|
Sakiris Spiro Kevin
Chief Financial Officer
|
+ 112727
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought
0 USD
|
Sakiris Spiro Kevin
Chief Financial Officer
|
+ 112727
|
0 USD |
|
1 year ago
Sep 01, 2023
|
Bought
92.5 USD
|
Simeonidis Harry
CEO
|
+ 50
|
1.85 USD |
|
1 year ago
Aug 31, 2023
|
Bought
192 USD
|
Simeonidis Harry
CEO
|
+ 100
|
1.92 USD |
7. News
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for clearance following FDA review of its Intelligent Fingerprinting Drug Screening System (the "System"), an innovative, rapid and pain-free method for drug screening. The submission represents a critical milestone on the Company's path to realizing its goal of entering the US market with its drug testing solution in 2025.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis, President & CEO and Spiro Sakiris, CFO at 4:30 p.m. ET on December 11, 2024.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions to Participate in the Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets' 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL.
globenewswire.com
- 1 month ago
INBS Stock Declines Despite Positive Results of Pharmacokinetic Study
Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.
zacks.com
- 2 months ago
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS' patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver Expanded distribution network in Saudi Arabia NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal first quarter ended September 30, 2024. The Company expects unaudited revenue of approximately $0.87 million for the three months ended September 30, 2024, representing an increase of 10% year-on-year and 20% quarter-on-quarter.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions to Present at the LD Micro Main Event XVII on October 28-30 in Los Angeles
New York, New York--(Newsfile Corp. - October 16, 2024) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present in the upcoming LD Micro Main Event XVII on October 28-30, 2024, in Los Angeles. LD Micro Main Event XVII Dates: October 28-30, 2024 Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA Presentation Day and Time: October 30 at 10:00 a.m.
newsfilecorp.com
- 3 months ago
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity
globenewswire.com
- 3 months ago
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency, with prominent clients across a wide range of industries, including mining, transportation and construction. Spirit Group will bring INBS' Intelligent Fingerprinting Drug Testing Solution to government and corporate clients across Australia.
globenewswire.com
- 3 months ago
GPS Marine Adopts Intelligent Bio Solutions' Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts.
globenewswire.com
- 3 months ago
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company's clinical study plan.
globenewswire.com
- 3 months ago
UK's Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions' Fingerprint Drug Test to Enhance Workplace Safety
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK's largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing.
globenewswire.com
- 3 months ago
8. Profile
Summary
Intelligent Bio Solutions Inc. INBS
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 6.68 M
Dividend Yield
0.00%
Description
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Contact
142 West 57th Street, New York, NY, 10019
https://gbs.inc
IPO
Date
Dec. 23, 2020
Employees
50
Officers
Mr. Harry Simeonidis
President & Chief Executive Officer
Mr. Alex Arzeno
Vice President of Investor Relations
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law
Chief Financial Officer